AZD6244 (Selumetinib) Clinical Trials

Size	Price	Qty
50mg	USD 147
200mg	USD 277

Clinical Trials

Numerous clinical trials evaluate selumetinib across diverse oncology and genetic indications, notably neurofibromatosis type 1—including plexiform neurofibromas, cutaneous neurofibromas, and optic nerve gliomas—as well as papillary thyroid carcinoma, biliary tract carcinoma, sarcomas, and advanced solid tumors. Spanning Early Phase 1 through Phase 3, these studies encompass actively recruiting, completed, and market-approved trials. Investigations are broadly supported by industry sponsors, including AstraZeneca and Merck Sharp & Dohme, alongside major public institutions such as the National Cancer Institute and the United States Department of Defense.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07713745	NOT_YET_RECRUITING	Neurofibromatosis Type 2; Vestibular Schwannoma; Non-vestibular Schwannoma; Meningioma; Ependymoma; NF2-related Schwannomatosis; NF2	Beijing Tiantan Hospital	2026-07-18	PHASE2
NCT06502171	RECRUITING	Neurofibromatosis 1; Plexiform Neurofibroma	Girish Dhall, MD	2026-06-09	PHASE1
NCT05253131	RECRUITING	MPNST; NF1; Sarcoma	University of Alabama at Birmingham	2026-08-04	PHASE2
NCT06188741	RECRUITING	Neurofibromatosis 1; Plexiform Neurofibroma	University of Alabama at Birmingham	2025-08-27	PHASE2
NCT02813135	RECRUITING	Pediatric Cancer	Gustave Roussy, Cancer Campus, Grand Paris	2016-08-03	PHASE1; PHASE2
NCT04166409	RECRUITING	Low Grade Astrocytoma; Low Grade Glioma; Metastatic Low Grade Astrocytoma; Metastatic Low Grade Glioma; WHO Grade 1 Glioma; WHO Grade 2 Glioma	National Cancer Institute (NCI)	2020-01-31	PHASE3
NCT05564377	RECRUITING	Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm	National Cancer Institute (NCI)	2023-04-07	PHASE2
NCT07707947	NOT_YET_RECRUITING	Neurofibromatosis Type 2; NF2; NF2-related Schwannomatosis; Meningioma; Ependymoma; Vestibular Schwannoma	Beijing Tiantan Hospital	2026-07-15	PHASE2
NCT05554328	ACTIVE_NOT_RECRUITING	Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma	National Cancer Institute (NCI)	2023-04-25	PHASE2
NCT06763315	NOT_YET_RECRUITING	Plexiform Neurofibromas (PN)	West China Hospital	2025-01-01	PHASE2
NCT02407405	ACTIVE_NOT_RECRUITING	Neurofibromatosis 1 (NF1); Plexiform Neurofibromas (PN)	National Cancer Institute (NCI)	2016-01-07	PHASE2
NCT03871257	ACTIVE_NOT_RECRUITING	Low Grade Glioma; Neurofibromatosis Type 1; Visual Pathway Glioma	National Cancer Institute (NCI)	2020-01-15	PHASE3
NCT05309668	ACTIVE_NOT_RECRUITING	Neurofibromatosis Type 1	AstraZeneca	2022-01-21	PHASE1; PHASE2
NCT06735820	RECRUITING	Malignant Peripheral Nerve Sheath Tumor (MPNST); Neurofibromatosis 1 (NF1); Atypical Neurofibroma	AeRang Kim	2026-06-01	PHASE1; PHASE2
NCT03326310	RECRUITING	Chronic Myeloid Leukemia; Myelofibroses	University of Chicago	2018-09-04	PHASE1
NCT03392246	ACTIVE_NOT_RECRUITING	Non-small Cell Lung Cancer	Dana-Farber Cancer Institute	2018-01-31	PHASE2
NCT02151084	ACTIVE_NOT_RECRUITING	Biliary Tract Carcinoma; Gallbladder Carcinoma	University Health Network, Toronto	2014-11	PHASE2
NCT01362803	ACTIVE_NOT_RECRUITING	Neurofibromatosis 1; Neurofibromatosis Type 1; NF1; Neurofibroma, Plexiform	National Cancer Institute (NCI)	2011-09-21	PHASE1; PHASE2
NCT04576117	ACTIVE_NOT_RECRUITING	Recurrent Low Grade Astrocytoma; Recurrent WHO Grade 2 Glioma; Refractory Low Grade Astrocytoma; Refractory Low Grade Glioma; Refractory WHO Grade 1 Glioma	National Cancer Institute (NCI)	2021-02-16	PHASE3
NCT06621082	NOT_YET_RECRUITING	Neurofibromatosis 1	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	2024-09-30	PHASE2
NCT06620354	NOT_YET_RECRUITING	Neurofibromatosis 1	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	2024-09-30	PHASE2
NCT07619521	NOT_YET_RECRUITING	Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma	National Cancer Institute (NCI)	2026-09-08	PHASE1; PHASE2
NCT03162627	ACTIVE_NOT_RECRUITING	Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Male Genital Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands	M.D. Anderson Cancer Center	2017-08-04	PHASE1
NCT05825365	WITHDRAWN	Neurofibromatosis Type 1; Plexiform Neurofibromas; Post-operative	AstraZeneca	2023-08-31	PHASE2
NCT01089101	ACTIVE_NOT_RECRUITING	Low Grade Glioma; Recurrent Childhood Pilocytic Astrocytoma; Recurrent Neurofibromatosis Type 1; Recurrent Visual Pathway Glioma; Refractory Neurofibromatosis Type 1; Refractory Visual Pathway Glioma	National Cancer Institute (NCI)	2010-07-07	PHASE1; PHASE2
NCT03581487	COMPLETED	Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8	M.D. Anderson Cancer Center	2019-04-01	PHASE1; PHASE2
NCT03944772	ACTIVE_NOT_RECRUITING	Non-Small Cell Lung Cancer	AstraZeneca	2019-06-25	PHASE2
NCT03155620	ACTIVE_NOT_RECRUITING	Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Langerhans Cell Histiocytosis; Malignant Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Soft Tissue Sarcoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Rhabdoid Tumor; Stage III Osteosarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Wilms Tumor	National Cancer Institute (NCI)	2017-07-31	PHASE2
NCT03801369	TERMINATED	Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma	Gordon Mills, MD, PhD	2018-12-12	PHASE2
NCT04924608	ACTIVE_NOT_RECRUITING	Neurofibromatosis 1; Plexiform Neurofibroma (PN)	AstraZeneca	2021-11-19	PHASE3
NCT05253131	Not yet recruiting	MPNST\|NF1\|Sarcoma	University of Alabama at Birmingham\|United States Department of Defense	2024-06-15	Phase 2
NCT03095248	TERMINATED	Neurofibromatosis 2; Vestibular Schwannoma; Meningioma; Ependymoma; Glioma	Children's Hospital Medical Center, Cincinnati	2017-05-08	PHASE2
NCT03326388	COMPLETED	Neurofibromatosis Type 1; Plexiform Neurofibroma; Optic Nerve Glioma	Great Ormond Street Hospital for Children NHS Foundation Trust	2019-09-26	PHASE1; PHASE2
NCT06175637	Recruiting	Neurofibroma Plexiform	AstraZeneca	2023-12-20	--
NCT02664935	COMPLETED	Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma	University of Birmingham	2015-05-13	PHASE2
NCT04348045	ACTIVE_NOT_RECRUITING	Metastatic Pancreatic Adenocarcinoma	GERCOR - Multidisciplinary Oncology Cooperative Group	2020-12-07	PHASE2
NCT03705507	TERMINATED	Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, Adult; Acute Lymphoblastic Leukemia, Pediatric; Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia Recurrent	University of Birmingham	2018-05-18	PHASE1; PHASE2
NCT03004105	WITHDRAWN	Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma; Advanced Lung Cancer; Recurrent Nonsmall Cell Lung Cancer	M.D. Anderson Cancer Center	2018-05	PHASE2
NCT05891847	Recruiting	Neurofibroma	AstraZeneca	2023-03-21	--
NCT02299999	ACTIVE_NOT_RECRUITING	Metastatic Breast Cancer	UNICANCER	2014-04-07	PHASE2
NCT02839720	COMPLETED	Cutaneous Neurofibroma; Neurofibromatosis Type 1; Optic Nerve Glioma	National Cancer Institute (NCI)	2017-08-26	PHASE2
NCT04590235	ACTIVE_NOT_RECRUITING	Neurofibromatosis 1; Neurofibroma Plexiform	AstraZeneca	2020-12-16	PHASE1
NCT03833427	TERMINATED	Advanced/Metastatic Solid Tumors	Merck Sharp & Dohme LLC	2019-03-18	PHASE1
NCT03433183	COMPLETED	Malignant Peripheral Nerve Sheath Tumors; Neurofibromatosis 1	Sarcoma Alliance for Research through Collaboration	2019-10-02	PHASE2
NCT05101148	ACTIVE_NOT_RECRUITING	Neurofibromatosis Type 1	AstraZeneca	2021-07-21	PHASE1
NCT05101148	Active not recruiting	Neurofibromatosis Type 1	AstraZeneca\|Merck Sharp & Dohme LLC	2021-07-21	Phase 1
NCT03213691	COMPLETED	Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm	National Cancer Institute (NCI)	2017-10-30	PHASE2
NCT04495127	COMPLETED	Neurofibromatosis Type 1	AstraZeneca	2020-08-31	PHASE1
NCT04879160	Completed	Neurofibromatosis 1	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	2021-05-12	--
NCT03745989	COMPLETED	Solid Tumors	Merck Sharp & Dohme LLC	2019-02-22	PHASE1
NCT01248247	COMPLETED	Lung Cancer	M.D. Anderson Cancer Center	2011-06-02	PHASE2
NCT02768766	COMPLETED	Uveal Melanoma	Shaheer A. Khan	2017-02-28	PHASE1
NCT02393690	COMPLETED	Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Carcinoma; Stage IV Thyroid Gland Follicular Carcinoma AJCC v7; Stage IV Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7	Academic and Community Cancer Research United	2015-05-04	PHASE2
NCT02503358	COMPLETED	Stage IIIB Non-Small Cell Lung Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7	OHSU Knight Cancer Institute	2016-07-21	PHASE1
NCT01586624	COMPLETED	Cancer; Non Small Cell Lung Cancer	Cancer Research UK	2012-01-10	PHASE1
NCT02546661	ACTIVE_NOT_RECRUITING	Muscle Invasive Bladder Cancer	AstraZeneca	2016-12-28	PHASE1
NCT02143466	ACTIVE_NOT_RECRUITING	Advanced Non Small Cell Lung Cancer	AstraZeneca	2014-08-05	PHASE1
NCT02583542	UNKNOWN	Triple-Negative Breast Cancer; Squamous Cell Lung Cancer; Non-squamous Cell Lung Cancer With KRAS Mutations; Non-squamous Cell Lung Cancer With Wild-type KRAS	Queen Mary University of London	2015-06	PHASE1; PHASE2
NCT01364051	ACTIVE_NOT_RECRUITING	Metastatic Melanoma; Refractory Malignant Solid Neoplasm; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Malignant Solid Neoplasm	National Cancer Institute (NCI)	2011-05-25	PHASE1
NCT02450656	UNKNOWN	Colorectal Neoplasms; Gastrointestinal Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung	The Netherlands Cancer Institute	2015-06	PHASE1; PHASE2
NCT03109301	WITHDRAWN	Neoplasms, Nerve Tissue; Neurofibromatosis 1; Heredodegenerative Disorders, Nervous System; Peripheral Nervous System Diseases	National Cancer Institute (NCI)	2017-04-07	PHASE2
NCT02117167	COMPLETED	Non-small Cell Lung Cancer Metastatic	UNICANCER	2014-04-23	PHASE2
NCT03649165	COMPLETED	Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs); Healthy Participants	AstraZeneca	2018-09-05	PHASE1
NCT03040986	COMPLETED	KRAS NP_004976.2:p.G12R; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7	National Cancer Institute (NCI)	2017-07-21	PHASE2
NCT02586987	COMPLETED	Lung Cancer; Melanoma; Head and Neck Carcinoma; Gastroesophageal Cancer; Breast Cancer; Pancreatic Adenocarcinoma; Colorectal Cancer; Biliary Tract Cancer	AstraZeneca	2015-12-28	PHASE1
NCT01843062	TERMINATED	Differentiated Thyroid Cancer	AstraZeneca	2013-08-27	PHASE3
NCT02448290	COMPLETED	Gastric Adenocarcinoma	Samsung Medical Center	2014-11-12	PHASE2
NCT02025114	COMPLETED	Non-small Cell Lung Cancer (NSCLC)	National Taiwan University Hospital	2014-09	PHASE1; PHASE2
NCT02685657	UNKNOWN	Triple Negative Breast Cancer	Russian Academy of Medical Sciences	2016-09	PHASE2
NCT02337530	COMPLETED	Non-Small Cell Lung Cancer	Canadian Cancer Trials Group	2015-05-26	PHASE2
NCT01783197	COMPLETED	Non Small Cell Lung Cancer	Canadian Cancer Trials Group	2013-06-04	PHASE1
NCT01146756	COMPLETED	Non Small Cell Lung Cancer	The Christie NHS Foundation Trust	2010-06-04	PHASE1
NCT02188264	COMPLETED	Recurrent Colorectal Carcinoma; Solid Neoplasm; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7	National Cancer Institute (NCI)	2014-08-29	PHASE1
NCT00559949	COMPLETED	Recurrent Thyroid Gland Carcinoma; Stage I Thyroid Gland Papillary Carcinoma; Stage II Thyroid Gland Papillary Carcinoma; Stage III Thyroid Gland Papillary Carcinoma; Stage IV Thyroid Gland Papillary Carcinoma	National Cancer Institute (NCI)	2007-12	PHASE2
NCT02179671	COMPLETED	Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)	AstraZeneca	2014-07-25	PHASE2
NCT01933932	ACTIVE_NOT_RECRUITING	Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV	AstraZeneca	2013-09-25	PHASE3
NCT01143402	COMPLETED	Iris Melanoma; Medium/Large Size Posterior Uveal Melanoma; Ocular Melanoma With Extraocular Extension; Recurrent Uveal Melanoma; Small Size Posterior Uveal Melanoma; Stage IV Uveal Melanoma	National Cancer Institute (NCI)	2010-06	PHASE2
NCT01750281	COMPLETED	Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV	AstraZeneca	2012-12-18	PHASE2
NCT01809210	COMPLETED	Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV	AstraZeneca	2013-04-04	PHASE1
NCT01011933	COMPLETED	Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Recurrent Uterine Corpus Carcinoma	National Cancer Institute (NCI)	2009-09	PHASE2
NCT01752569	TERMINATED	AIDS-related Kaposi's Sarcoma	Sheffield Teaching Hospitals NHS Foundation Trust	2012-06-15	PHASE1; PHASE2
NCT01658943	COMPLETED	Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	2012-08	PHASE2
NCT01974752	COMPLETED	Metastatic; Uveal Melanoma	AstraZeneca	2014-04	PHASE3
NCT01605916	COMPLETED	Neoplasms,; Metastatic Cancer,; Non-Small Cell Lung Cancer; Advanced Solid Malignancies	AstraZeneca	2012-06	PHASE1
NCT01206140	COMPLETED	Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma	National Cancer Institute (NCI)	2010-10	PHASE2
NCT02322749	COMPLETED	Healthy Volunteers Bioequivalence or Bioavailability Study	AstraZeneca	2015-02	PHASE1
NCT00888134	COMPLETED	Adult Solid Neoplasm	National Cancer Institute (NCI)	2009-07	PHASE2
NCT02238782	COMPLETED	Healthy Volunteers Bioavailability Study	AstraZeneca	2014-10	PHASE1
NCT02063230	COMPLETED	Solid Tumors	AstraZeneca	2014-03	PHASE1
NCT02056392	COMPLETED	Solid Tumours	AstraZeneca	2014-03	PHASE1
NCT01949870	TERMINATED	Inoperable Locally Advanced or Metastatic Biliary Tract Cancer	AstraZeneca	2013-10	PHASE1
NCT02063204	COMPLETED	Solid Tumours	AstraZeneca	2014-03	PHASE1
NCT02093728	COMPLETED	Solid Tumours	AstraZeneca	2014-04	PHASE1
NCT01960374	COMPLETED	Healthy Volunteers Pharmacokinetic Study	AstraZeneca	2013-10	PHASE1
NCT00780676	TERMINATED	Breast Cancer	M.D. Anderson Cancer Center	2009-06	PHASE2
NCT02046850	COMPLETED	Solid Tumours	AstraZeneca	2014-02	PHASE1
NCT01313039	COMPLETED	Breast Cancer	University of Miami	2011-02	EARLY_PHASE1
NCT01306045	COMPLETED	Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell Lung; Carcinoma, Thymic	National Cancer Institute (NCI)	2011-02-08	PHASE2
NCT01974349	COMPLETED	Solid Tumours	AstraZeneca	2013-11	PHASE1
NCT01278615	TERMINATED	Recurrent Adult Diffuse Large Cell Lymphoma	National Cancer Institute (NCI)	2010-12	PHASE2
NCT01029418	TERMINATED	Hepatocellular Carcinoma	National Cancer Centre, Singapore	2009-11	PHASE1; PHASE2
NCT01931761	COMPLETED	Solid Tumours	AstraZeneca	2013-10	PHASE1
NCT01333475	COMPLETED	Colorectal Neoplasms	National Cancer Institute (NCI)	2011-03	PHASE2
NCT01160926	TERMINATED	Rectal Cancer	The Christie NHS Foundation Trust	2010-07	PHASE1
NCT01229150	COMPLETED	Non Small Cell Lung Carcinoma	National Cancer Institute (NCI)	2010-10-26	PHASE2
NCT00866177	COMPLETED	Recurrent Melanoma; Stage III Skin Melanoma; Stage IV Skin Melanoma	National Cancer Institute (NCI)	2009-03	PHASE2
NCT01287130	COMPLETED	Colonic Neoplasms; Cancer of the Colon; Colon Cancer; Colon Neoplasms; Colonic Cancer	National Cancer Institute (NCI)	2011-01-07	PHASE1
NCT00551070	COMPLETED	Borderline Ovarian Serous Tumor; Low Grade Ovarian Serous Adenocarcinoma; Micropapillary Serous Carcinoma; Primary Peritoneal Carcinoma; Primary Peritoneal Low Grade Serous Adenocarcinoma; Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor	National Cancer Institute (NCI)	2007-12-17	PHASE2
NCT01859182	WITHDRAWN	Adenocarcinoma of the Gallbladder; Adenocarcinoma With Squamous Metaplasia of the Gallbladder; Adult Primary Cholangiocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Localized Unresectable Adult Primary Liver Cancer; Metastatic Extrahepatic Bile Duct Cancer; Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer; Stage II Gallbladder Cancer; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Cancer	National Cancer Institute (NCI)	2013-01	PHASE2
NCT01519427	TERMINATED	Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma	National Cancer Institute (NCI)	2012-01	PHASE2
NCT01222689	COMPLETED	Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	2010-11	PHASE2
NCT01061749	COMPLETED	Adult Solid Neoplasm	National Cancer Institute (NCI)	2009-11	PHASE1
NCT00970359	COMPLETED	Thyroid Cancer	Memorial Sloan Kettering Cancer Center	2009-09
NCT01242605	COMPLETED	Biliary Tract Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms	University College, London	2012-02	PHASE1
NCT00553332	COMPLETED	Liver and Intrahepatic Biliary Tract Cancer; Recurrent Extrahepatic Bile Duct Cancer; Unresectable Extrahepatic Bile Duct Cancer	National Cancer Institute (NCI)	2007-11	PHASE2
NCT01160718	COMPLETED	Breast Cancer	Swiss Cancer Institute	2010-08	PHASE2
NCT01217450	COMPLETED	Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific	National Cancer Institute (NCI)	2012-10	PHASE1
NCT01021748	COMPLETED	Locally Advanced or Metastatic Solid Tumors	Merck Sharp & Dohme LLC	2009-11-23	PHASE1
NCT01134601	TERMINATED	Non-Metastatic Adenocarcinoma of the Rectum	National Cancer Institute (NCI)	2010-05-24	PHASE1
NCT01256359	COMPLETED	Melanoma	University of Oxford	2010-10	PHASE2
NCT01635023	COMPLETED	Healthy Volunteers	AstraZeneca	2012-07	PHASE1
NCT01116271	COMPLETED	Colorectal Cancer	AstraZeneca	2010-04	PHASE2
NCT00604721	COMPLETED	Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer	National Cancer Institute (NCI)	2007-11	PHASE2
NCT01166126	TERMINATED	Mucosal Melanoma; Recurrent Melanoma; Stage IV Melanoma	National Cancer Institute (NCI)	2010-10	PHASE2
NCT00588809	COMPLETED	Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Promyelocytic Leukemia (M3); Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia	National Cancer Institute (NCI)	2007-12	PHASE2
NCT01085214	COMPLETED	Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma	National Cancer Institute (NCI)	2010-03	PHASE2
NCT00936221	COMPLETED	Melanoma	AstraZeneca	2009-07	PHASE2
NCT00890825	COMPLETED	Non Small Cell Lung Cancer	AstraZeneca	2009-04-20	PHASE2
NCT00600496	COMPLETED	Breast Cancer; Breast Neoplasms; Colon Cancer; Colonic Cancer; Colon Neoplasms; Lung Cancer; Melanoma; Kidney Cancer	AstraZeneca	2007-12-14	PHASE1
NCT00710515	COMPLETED	Melanoma; Malignant Melanoma	AstraZeneca	2008-07	PHASE1
NCT00463814	ACTIVE_NOT_RECRUITING	Tumor; Cancer	AstraZeneca	2007-03-08	PHASE1
NCT00372944	COMPLETED	Pancreatic Cancer	AstraZeneca	2006-08	PHASE2
NCT00338130	COMPLETED	Melanoma	AstraZeneca	2006-07	PHASE2
NCT00372788	COMPLETED	Non-small Cell Lung Cancer	AstraZeneca	2006-08	PHASE2
NCT00514761	COMPLETED	Metastatic Colorectal Cancer	AstraZeneca	2006-09	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-20)

Check the AZD6244 (Selumetinib) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Selumetinib (AZD6244) potently and selectively binds to mitogen-activated protein kinase kinase 1 (MEK1) and MEK2, inhibiting catalytic activity and preventing downstream phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) within the MAPK signaling pathway. This biochemical inhibition suppresses cellular proliferation, impairs migration, and triggers apoptosis, translating clinically to tumor regression and disease stabilization in RAS-RAF-driven pathologies such as neurofibromatosis type 1-associated plexiform neurofibromas and papillary thyroid carcinoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).